YolTech Therapeutics
PrivateLast Round
Series C
May 28, 2026
Total Funding Raised
$147M
Company Overview
YolTech Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series C round in May 2026.
YolTech Therapeutics is a biotechnology company that develops in vivo gene-editing therapies for serious genetic, metabolic, and cardiovascular diseases using proprietary CRISPR-Cas and lipid nanoparticle delivery platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
YolTech Therapeutics Comparables
Compare YolTech Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arbor Biotechnologies | 83% | |
| CorrectSequence Therapeutics | 82% | |
| Base Therapeutics | 82% |
For institutional investors. Book with your work email.
YolTech Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 28, 2026 | ||||
| Series B | Sep 11, 2025 | ||||
| Series A Extension | Nov 1, 2023 | ||||
| Series A | Aug 1, 2022 |
For institutional investors. Book with your work email.
YolTech Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Loyal Valley Capital | Series C |
| Unity Ventures | Series A |
| 险峰K2VC | Series C, Series A |
| 松禾资本 (Green Pine Capital Partners) | Series B |
| Decheng Capital | Series B, Series A Extension |
| Grand Flight Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2025
$45M round led by AstraZeneca-CICC Healthcare Industrial Fund.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_issues_withOct 2, 2026
On Oct 2nd '26 in New York, Beam Therapeutics sued Yoltx and others over the alleged use of trade secrets to develop a gene editor for alpha-1 antitrypsin deficiency.
- has_issues_withOct 2, 2026
Yoltx faces Beam Therapeutics' lawsuit in New York over alleged trade secrets theft involving development of a gene editor for alpha-1 antitrypsin deficiency on Oct 2nd '26.
- has_issues_withSep 29, 2026
A lawsuit filed by Beam Therapeutics accuses Yoltx of tech theft, alleging its lipid patent application and AATD program incorporate Beam’s proprietary technology, as reported on Sep 29th '26.
- attends_eventAug 31, 2026
Yoltx attends the European Society of Cardiology (ESC) Congress 2026 in Germany from Aug 28th–31st '26, where initial clinical data from an investigator-initiated YOLT-201 trial in ATTR-CM patients are presented.
For institutional investors. Book with your work email.
YolTech Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about YolTech Therapeutics's valuation, stock price, and market status.
Is YolTech Therapeutics a public or private company?
YolTech Therapeutics is a private company.
What is the current stock price of YolTech Therapeutics?
YolTech Therapeutics is a private company, so its shares have no public market price. Caplight tracks YolTech Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is YolTech Therapeutics worth (valuation)?
Valuation information for YolTech Therapeutics is not publicly available.
Can I buy YolTech Therapeutics stock?
YolTech Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was YolTech Therapeutics's last funding round?
YolTech Therapeutics's most recent funding round was Series C on May 28, 2026.
Who are the main investors in YolTech Therapeutics?
Key investors in YolTech Therapeutics include Loyal Valley Capital, Decheng Capital.
Will YolTech Therapeutics IPO soon?
No public IPO plans have been announced for YolTech Therapeutics.
How can I track YolTech Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in YolTech Therapeutics's shares on secondary markets.